|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gluer AM, Cocco N, Laurence JM, Johnston
ES, Hollands MJ, Pleass HC, Richardson AJ and Lam VW: Systematic
review of actual 10-year survival following resection for
hepatocellular carcinoma. HPB (Oxford). 14:285–290. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Greene PJ and Sussman HH: Structual
comparison of ectopic and normal placental alkaline phosphatase.
Proc Natl Acad Sci USA. 70:2936–2940. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu MC, Chan KM, Lee CF, Lee YS, Eldeen FZ,
Chou HS, Lee WC and Chen MF: Alkaline phosphatase: Does it have a
role in predicting hepatocellular carcinoma recurrence? J
Gastrointest Surg. 15:1440–1449. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liao FL, Peng DH, Chen W, Hu HN, Tang P,
Liu YY, Luo Y and Yao T: Evaluation of serum hepatic enzyme
activities in different COVID-19 phenotypes. J Med Virol.
93:2365–2373. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McMillan DC, Watson WS, O'Gorman P,
Preston T, Scott HR and McArdle CS: Albumin concentrations are
primarily determined by the body cell mass and the systemic
inflammatory response in cancer patients with weight loss. Nutr
Cancer. 39:210–213. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Dai Y, Zhou F, Long Z, Li Y, Liu B,
Xie D, Tang J, Tan J, Yao K, et al: The prognostic role of
preoperative serum albumin/globulin ratio in patients with bladder
urothelial carcinoma undergoing radical cystectomy. Urol Oncol.
34:484.e1–484.e8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu YQ, Li J, Liao Y, Chen Q, Liao WJ and
Huang J: The preoperative alkaline phosphatase-to-platelet ratio
index is an independent prognostic factor for hepatocellular
carcinoma after hepatic resection. Medicine (Baltimore).
95:e57342016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jin J, Zhu P, Liao Y, Li J, Liao W and He
S: Elevated preoperative aspartate aminotransferase to lymphocyte
ratio index as an independent prognostic factor for patients with
hepatocellular carcinoma after hepatic resection. Oncotarget.
6:19217–19227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suh B, Park S, Shin DW, Yun JM, Keam B,
Yang HK, Ahn E, Lee H, Park JH and Cho B: Low albumin-to-globulin
ratio associated with cancer incidence and mortality in generally
healthy adults. Ann Oncol. 25:2260–2266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou M, Luo J, Chen M, Yang H, Learned RM,
DePaoli AM, Tian H and Ling L: Mouse species-specific control of
hepatocarcinogenesis and metabolism by FGF19/FGF15. J Hepatol.
66:1182–1192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu AX, Abbas AR, de Galarreta MR, Guan Y,
Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, et al: Molecular
correlates of clinical response and resistance to atezolizumab in
combination with bevacizumab in advanced hepatocellular carcinoma.
Nat Med. 28:1599–1611. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Izquierdo-Sanchez L, Lamarca A, La Casta
A, Buettner S, Utpatel K, Klümpen HJ, Adeva J, Vogel A, Lleo A,
Fabris L, et al: Cholangiocarcinoma landscape in Europe:
Diagnostic, prognostic and therapeutic insights from the ENSCCA
Registry. J Hepatol. 76:1109–1121. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singhi AD, Nikiforova MN, Chennat J,
Papachristou GI, Khalid A, Rabinovitz M, Das R, Sarkaria S, Ayasso
MS, Wald AI, et al: Integrating next-generation sequencing to
endoscopic retrograde cholangiopancreatography (ERCP)-obtained
biliary specimens improves the detection and management of patients
with malignant bile duct strictures. Gut. 69:52–61. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao
C, Huang F, Tang R, Cheng Y, Huang Z, et al: Lenvatinib combined
with transarterial chemoembolization as first-line treatment for
advanced hepatocellular carcinoma: A phase III, randomized clinical
trial (LAUNCH). J Clin Oncol. 41:117–127. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li
SL, Deng HJ, He M, Mu LW and Zhao M: Arterial chemotherapy of
oxaliplatin plus fluorouracil versus sorafenib in advanced
hepatocellular carcinoma: A biomolecular exploratory, randomized,
phase III trial (FOHAIC-1). J Clin Oncol. 40:468–480. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rimassa L, Personeni N, Czauderna C,
Foerster F and Galle P: Systemic treatment of HCC in special
populations. J Hepatol. 74:931–943. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng D, Xu W, Gong X, Yuan L and Zhang
XB: Design strategy of fluorescent probes for live drug-induced
acute liver injury imaging. Acc Chem Res. 54:403–415. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Aerts RMM, van de Laarschot LFM,
Banales JM and Drenth JPH: Clinical management of polycystic liver
disease. J Hepatol. 68:827–837. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Y, Huang S, Wang J, Sun L, Zeng F and
Wu S: Activatable probes for diagnosing and positioning liver
injury and metastatic tumors by multispectral optoacoustic
tomography. Nat Commun. 9:39832018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kemeny NE, Chou JF, Capanu M, Chatila WK,
Shi H, Sanchez-Vega F, Kingham TP, Connell LC, Jarnagin WR and
D'Angelica MI: A randomized phase II trial of adjuvant hepatic
arterial infusion and systemic therapy with or without panitumumab
after hepatic resection of KRAS Wild-type colorectal cancer. Ann
Surg. 274:248–254. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seto WK, Lo YR, Pawlotsky JM and Yuen MF:
Chronic hepatitis B virus infection. Lancet. 392:2313–2324. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim HS, Yu X, Kramer J, Thrift AP,
Richardson P, Hsu YC, Flores A, El-Serag HB and Kanwal F:
Comparative performance of risk prediction models for hepatitis
B-related hepatocellular carcinoma in the United States. J Hepatol.
76:294–301. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kulik L and El-Serag HB: Epidemiology and
management of hepatocellular carcinoma. Gastroenterology.
156:477–491.e1. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shih C, Yang CC, Choijilsuren G, Chang CH
and Liou AT: Hepatitis B Virus. Trends Microbiol. 26:386–387. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zou Y, Qazvini NT, Zane K, Sadati M, Wei
Q, Liao J, Fan J, Song D, Liu J, Ma C, et al: Mgelatin-derived
graphene-silicate hybrid materials are biocompatible and
synergistically promote BMP9-Induced osteogenic differentiation of
mesenchymal stem cells. ACS Appl Mater Interfaces. 9:15922–15932.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
al-Rashida M and Iqbal J: Iqbal,
Inhibition of alkaline phosphatase: An emerging new drug target.
Mini Rev Med Chem. 15:41–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamamoto K, Awogi T, Okuyama K and
Takahashi N: Nuclear localization of alkaline phosphatase in
cultured human cancer cells. Med Electron Microsc. 36:47–51. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Muñoz-González JI, Álvarez-Twose I,
Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, Sperr WR,
Shoumariyeh K, Schwaab J, Greiner G, et al: Proposed global
prognostic score for systemic mastocytosis: A retrospective
prognostic modelling study. Lancet Haematol. 8:e194–e204. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou H, Du W, Li Y, Shi C, Hu N, Ma S,
Wang W and Ren J: Effects of melatonin on fatty liver disease: The
role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission, and
mitophagy. J Pineal Res. 642018.
|
|
32
|
Villa-Bellosta R, González-Parra E and
Egido J: Alkalosis and dialytic clearance of phosphate increases
phosphatase activity: A hidden consequence of hemodialysis. PLoS
One. 11:e01598582016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takagi A, Hawke P, Tokuda S, Toda T,
Higashizono K, Nagai E, Watanabe M, Nakatani E, Kanemoto H and Oba
N: Serum carnitine as a biomarker of sarcopenia and nutritional
status in preoperative gastrointestinal cancer patients. J Cachexia
Sarcopenia Muscle. 13:287–295. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garcia-Martinez R, Caraceni P, Bernardi M,
Gines P, Arroyo V and Jalan R: Albumin: Pathophysiologic basis of
its role in the treatment of cirrhosis and its complications.
Hepatology. 58:1836–1846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vincent JL, Russell JA, Jacob M, Martin G,
Guidet B, Wernerman J, Ferrer R, McCluskey SA and Gattinoni L:
Albumin administration in the acutely ill: What is new and where
next? Crit Care. 18:2312014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
China L, Freemantle N, Forrest E, Kallis
Y, Ryder SD, Wright G, Portal AJ, Becares Salles N, Gilroy DW and
O'Brien A; ATTIRE Trial Investigators, : A randomized trial of
albumin infusions in hospitalized patients with cirrhosis. N Engl J
Med. 384:808–817. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wong F, Pappas SC, Curry MP, Reddy KR,
Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA,
et al: Terlipressin plus albumin for the treatment of type 1
hepatorenal syndrome. N Engl J Med. 384:818–828. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boada M, López OL, Olazarán J, Núñez L,
Pfeffer M, Paricio M, Lorites J, Piñol-Ripoll G, Gámez JE, Anaya F,
et al: A randomized, controlled clinical trial of plasma exchange
with albumin replacement for Alzheimer's disease: Primary results
of the AMBAR Study. Alzheimers Dement. 16:1412–1425. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carr BI and Guerra V: Serum albumin levels
in relation to tumor parameters in hepatocellular carcinoma
patients. Int J Biol Markers. 32:e391–e396. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bağırsakçı E, Şahin E, Atabey N, Erdal E,
Guerra V and Carr BI: Role of albumin in growth inhibition in
hepatocellular carcinoma. Oncology. 93:136–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ram AK, Pottakat B and Vairappan B:
Increased systemic zonula occludens 1 associated with inflammation
and independent biomarker in patients with hepatocellular
carcinoma. BMC Cancer. 18:5722018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lv LL, Feng Y, Wen Y, Wu WJ, Ni HF, Li ZL,
Zhou LT, Wang B, Zhang JD, Crowley SD and Liu BC: Exosomal CCL2
from tubular epithelial cells is critical for albumin-induced
tubulointerstitial inflammation. J Am Soc Nephrol. 29:919–935.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sapienza C and Issa JP: Nutrition, and
cancer epigenetics. Annu Rev Nutr. 36:665–681. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kaymak I, Williams KS, Cantor JR and Jones
RG: Immunometabolic interplay in the tumor microenvironment. Cancer
Cell. 39:28–37. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Esper DH and Harb WA: The cancer cachexia
syndrome: A review of metabolic and clinical manifestations. Nutr
Clin Pract. 20:369–376. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Atasheva S, Emerson CC, Yao J, Young C,
Stewart PL and Shayakhmetov DM: Systemic cancer therapy with
engineered adenovirus that evades innate immunity. Sci Transl Med.
12:eabc66592020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gola A, Dorrington MG, Speranza E, Sala C,
Shih RM, Radtke AJ, Wong HS, Baptista AP, Hernandez JM, Castellani
G, et al: Commensal-driven immune zonation of the liver promotes
host defence. Nature. 589:131–136. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ringelhan M, Pfister D, O'Connor T,
Pikarsky E and Heikenwalder M: The immunology of hepatocellular
carcinoma. Nat Immunol. 19:222–232. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Limketkai BN, Mehta SH, Sutcliffe CG,
Higgins YM, Torbenson MS, Brinkley SC, Moore RD, Thomas DL and
Sulkowski MS: Relationship of liver disease stage and antiviral
therapy with liver-related events and death in adults coinfected
with HIV/HCV. JAMA. 308:370–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Carrat F, Fontaine H, Dorival C, Simony M,
Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki
JP, et al: Clinical outcomes in patients with chronic hepatitis C
after direct-acting antiviral treatment: A prospective cohort
study. Lancet. 393:1453–1464. 2019. View Article : Google Scholar : PubMed/NCBI
|
